Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis: a Two-stage Interventional, Prospective, Open-label, Phase I/II Trial in Patients With Active, Treatment Refractory, ANCA-IgG-positive Vasculitis

NCT06590545 is registered in ClinicalTrials.gov with David Simon as lead sponsor.

NCT NCT06590545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06590545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis: a Two-stage Interventional, Prospective, Open-label, Phase I/II Trial in Patients With Active, Treatment Refractory, ANCA-IgG-positive Vasculitis
Lead sponsor
David Simon
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 31, 2025
Completion date
July 31, 2027
Enrollment
8 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anca-igg-positive anca associated vasculitis